KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Amneal Pharmaceuticals (AMRX) Receivables - Net (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Receivables - Net data on record, last reported at $895.1 million in Q4 2025.

  • For Q4 2025, Receivables - Net changed N/A year-over-year to $895.1 million; the TTM value through Dec 2025 reached $895.1 million, changed N/A, while the annual FY2025 figure was $895.1 million, 200155.7% up from the prior year.
  • Receivables - Net reached $895.1 million in Q4 2025 per AMRX's latest filing, down from $1.4 billion in the prior quarter.
  • Across five years, Receivables - Net topped out at $1.4 billion in Q3 2025 and bottomed at $954000.0 in Q4 2023.
  • Average Receivables - Net over 5 years is $949.5 million, with a median of $1.1 billion recorded in 2021.
  • Peak YoY movement for Receivables - Net: dropped 26.58% in 2021, then skyrocketed 85.42% in 2023.
  • A 5-year view of Receivables - Net shows it stood at $662.6 million in 2021, then soared by 55.17% to $1.0 billion in 2022, then plummeted by 99.91% to $954000.0 in 2023, then skyrocketed by 127092.56% to $1.2 billion in 2024, then decreased by 26.23% to $895.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Net were $895.1 million in Q4 2025, $1.4 billion in Q3 2025, and $1.3 billion in Q2 2025.